 Cristos Ifantides
Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cataract | 8 | 2023 | 238 | 2.840 |
Why?
| | Cataract Extraction | 5 | 2025 | 120 | 2.380 |
Why?
| | Dry Eye Syndromes | 6 | 2026 | 56 | 1.780 |
Why?
| | Lenses, Intraocular | 4 | 2022 | 49 | 1.480 |
Why?
| | Ophthalmology | 2 | 2023 | 119 | 1.360 |
Why?
| | Anterior Eye Segment | 1 | 2025 | 10 | 0.930 |
Why?
| | Capsulorhexis | 2 | 2022 | 9 | 0.920 |
Why?
| | Ciliary Body | 1 | 2025 | 40 | 0.910 |
Why?
| | Lens Subluxation | 2 | 2025 | 4 | 0.900 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2025 | 90 | 0.850 |
Why?
| | Posterior Capsulotomy | 1 | 2022 | 8 | 0.760 |
Why?
| | Lens Capsule, Crystalline | 1 | 2022 | 13 | 0.750 |
Why?
| | Clinical Decision-Making | 1 | 2026 | 362 | 0.750 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 80 | 0.740 |
Why?
| | Weapons | 1 | 2021 | 8 | 0.670 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.670 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.660 |
Why?
| | Eye Injuries | 1 | 2021 | 53 | 0.640 |
Why?
| | Granuloma, Foreign-Body | 1 | 2020 | 8 | 0.620 |
Why?
| | Tattooing | 1 | 2020 | 12 | 0.620 |
Why?
| | Language | 1 | 2023 | 322 | 0.600 |
Why?
| | Hepatitis C | 1 | 2022 | 256 | 0.600 |
Why?
| | Health Status Disparities | 1 | 2023 | 320 | 0.600 |
Why?
| | Macular Edema | 1 | 2020 | 49 | 0.590 |
Why?
| | Glaucoma, Open-Angle | 2 | 2021 | 104 | 0.550 |
Why?
| | Uveitis | 1 | 2020 | 149 | 0.550 |
Why?
| | Postoperative Complications | 5 | 2025 | 2961 | 0.540 |
Why?
| | Practice Patterns, Physicians' | 1 | 2026 | 1365 | 0.500 |
Why?
| | Healthcare Disparities | 1 | 2023 | 731 | 0.470 |
Why?
| | Nocardia | 1 | 2015 | 6 | 0.440 |
Why?
| | Nocardia Infections | 1 | 2015 | 11 | 0.440 |
Why?
| | Eye Infections, Bacterial | 1 | 2015 | 45 | 0.420 |
Why?
| | Internship and Residency | 1 | 2023 | 1264 | 0.360 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 10 | 0.350 |
Why?
| | Surgical Wound Infection | 1 | 2015 | 329 | 0.340 |
Why?
| | Phacoemulsification | 2 | 2023 | 123 | 0.340 |
Why?
| | Lens Implantation, Intraocular | 2 | 2022 | 80 | 0.340 |
Why?
| | Retrospective Studies | 8 | 2023 | 17247 | 0.280 |
Why?
| | Trabeculectomy | 2 | 2021 | 75 | 0.260 |
Why?
| | Humans | 25 | 2026 | 145140 | 0.260 |
Why?
| | Optometrists | 1 | 2026 | 12 | 0.240 |
Why?
| | Ophthalmologists | 1 | 2026 | 20 | 0.240 |
Why?
| | Sclera | 1 | 2025 | 36 | 0.230 |
Why?
| | Vitrectomy | 1 | 2025 | 73 | 0.220 |
Why?
| | Hypothermia, Induced | 1 | 2025 | 95 | 0.210 |
Why?
| | Refraction, Ocular | 2 | 2022 | 47 | 0.210 |
Why?
| | Masks | 1 | 2023 | 70 | 0.190 |
Why?
| | Corneal Injuries | 1 | 2023 | 42 | 0.190 |
Why?
| | Anesthetics, Local | 1 | 2023 | 104 | 0.180 |
Why?
| | Photorefractive Keratectomy | 1 | 2022 | 21 | 0.180 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2022 | 20 | 0.180 |
Why?
| | Intraocular Pressure | 3 | 2025 | 329 | 0.180 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2022 | 82 | 0.180 |
Why?
| | Glaucoma Drainage Implants | 1 | 2022 | 46 | 0.180 |
Why?
| | Alanine Transaminase | 1 | 2022 | 151 | 0.180 |
Why?
| | United States | 4 | 2024 | 16065 | 0.170 |
Why?
| | Safety-net Providers | 1 | 2023 | 129 | 0.170 |
Why?
| | Intraoperative Complications | 1 | 2022 | 157 | 0.170 |
Why?
| | Dissent and Disputes | 1 | 2021 | 18 | 0.170 |
Why?
| | Aberrometry | 1 | 2020 | 9 | 0.170 |
Why?
| | Hepacivirus | 1 | 2022 | 242 | 0.160 |
Why?
| | Republic of Korea | 1 | 2020 | 43 | 0.160 |
Why?
| | Crowding | 1 | 2021 | 37 | 0.160 |
Why?
| | Optics and Photonics | 1 | 2020 | 37 | 0.160 |
Why?
| | Visual Acuity | 2 | 2022 | 491 | 0.160 |
Why?
| | Myopia | 1 | 2020 | 59 | 0.160 |
Why?
| | Adalimumab | 1 | 2020 | 55 | 0.150 |
Why?
| | Foreign-Body Reaction | 1 | 2020 | 34 | 0.150 |
Why?
| | Benchmarking | 1 | 2020 | 188 | 0.150 |
Why?
| | Glaucoma | 1 | 2022 | 250 | 0.150 |
Why?
| | Steroids | 1 | 2020 | 160 | 0.140 |
Why?
| | Health Surveys | 1 | 2021 | 517 | 0.140 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5886 | 0.140 |
Why?
| | Glucocorticoids | 1 | 2022 | 531 | 0.140 |
Why?
| | Ambulatory Care | 1 | 2023 | 608 | 0.130 |
Why?
| | Education, Medical, Graduate | 1 | 2023 | 562 | 0.130 |
Why?
| | Biopsy | 1 | 2020 | 1079 | 0.120 |
Why?
| | Surveys and Questionnaires | 2 | 2026 | 6055 | 0.120 |
Why?
| | Curriculum | 1 | 2023 | 1067 | 0.120 |
Why?
| | Surgical Stomas | 1 | 2015 | 10 | 0.110 |
Why?
| | Amikacin | 1 | 2015 | 29 | 0.110 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2015 | 43 | 0.110 |
Why?
| | Clinical Competence | 1 | 2023 | 1240 | 0.110 |
Why?
| | Male | 9 | 2026 | 72664 | 0.110 |
Why?
| | Tomography, Optical Coherence | 1 | 2015 | 271 | 0.090 |
Why?
| | Middle Aged | 4 | 2026 | 36126 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1043 | 0.090 |
Why?
| | Cornea | 2 | 2023 | 154 | 0.090 |
Why?
| | Sports Equipment | 1 | 2011 | 9 | 0.080 |
Why?
| | Rabbits | 3 | 2025 | 652 | 0.080 |
Why?
| | Risk Factors | 2 | 2022 | 10857 | 0.080 |
Why?
| | Equipment Contamination | 1 | 2011 | 67 | 0.080 |
Why?
| | Staphylococcal Skin Infections | 1 | 2011 | 40 | 0.080 |
Why?
| | Receptors, CCR2 | 1 | 2009 | 38 | 0.080 |
Why?
| | Transplants | 1 | 2009 | 38 | 0.080 |
Why?
| | Shear Strength | 1 | 2009 | 73 | 0.070 |
Why?
| | Tunica Intima | 1 | 2009 | 78 | 0.070 |
Why?
| | Veins | 1 | 2009 | 69 | 0.070 |
Why?
| | Community-Acquired Infections | 1 | 2011 | 177 | 0.070 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2008 | 31 | 0.070 |
Why?
| | Graft Occlusion, Vascular | 1 | 2008 | 40 | 0.070 |
Why?
| | Prospective Studies | 1 | 2020 | 8035 | 0.070 |
Why?
| | Adult | 5 | 2024 | 40665 | 0.070 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2011 | 250 | 0.070 |
Why?
| | Female | 6 | 2026 | 78636 | 0.070 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 46 | 0.060 |
Why?
| | Jugular Veins | 1 | 2007 | 42 | 0.060 |
Why?
| | Blood Vessels | 1 | 2008 | 167 | 0.060 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2008 | 266 | 0.060 |
Why?
| | C-Reactive Protein | 1 | 2008 | 422 | 0.060 |
Why?
| | Epithelium, Corneal | 1 | 2025 | 41 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2007 | 376 | 0.060 |
Why?
| | Incidence | 2 | 2022 | 2915 | 0.060 |
Why?
| | Prevalence | 2 | 2022 | 2855 | 0.050 |
Why?
| | Graft Survival | 1 | 2007 | 517 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 474 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1922 | 0.050 |
Why?
| | Tears | 1 | 2023 | 27 | 0.050 |
Why?
| | Loteprednol Etabonate | 1 | 2022 | 5 | 0.050 |
Why?
| | Lubricant Eye Drops | 1 | 2022 | 9 | 0.050 |
Why?
| | Meibomian Glands | 1 | 2022 | 15 | 0.050 |
Why?
| | Osteogenesis Imperfecta | 1 | 2022 | 14 | 0.050 |
Why?
| | Tobramycin | 1 | 2022 | 63 | 0.050 |
Why?
| | Lasers, Excimer | 1 | 2022 | 30 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2022 | 5411 | 0.040 |
Why?
| | Communication Barriers | 1 | 2023 | 130 | 0.040 |
Why?
| | Cyclosporine | 1 | 2022 | 256 | 0.040 |
Why?
| | Mitomycin | 1 | 2021 | 32 | 0.040 |
Why?
| | Fibroblasts | 1 | 2007 | 1022 | 0.040 |
Why?
| | Analgesics | 1 | 2023 | 230 | 0.040 |
Why?
| | Prosthesis Implantation | 1 | 2022 | 154 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 169 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 69 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 343 | 0.040 |
Why?
| | India | 1 | 2020 | 213 | 0.040 |
Why?
| | Cell Movement | 3 | 2009 | 959 | 0.040 |
Why?
| | Global Health | 1 | 2022 | 403 | 0.040 |
Why?
| | Disease Outbreaks | 1 | 2022 | 419 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2022 | 483 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 732 | 0.030 |
Why?
| | Aged | 3 | 2023 | 26096 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2022 | 11741 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1742 | 0.030 |
Why?
| | Signal Transduction | 1 | 2009 | 5208 | 0.030 |
Why?
| | Research Design | 1 | 2021 | 1132 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2022 | 3616 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2025 | 4552 | 0.030 |
Why?
| | Adolescent | 2 | 2023 | 22479 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2020 | 1188 | 0.020 |
Why?
| | Animals | 3 | 2025 | 37952 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2009 | 112 | 0.020 |
Why?
| | Hyperplasia | 1 | 2009 | 177 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2008 | 148 | 0.020 |
Why?
| | Elastin | 1 | 2008 | 78 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 8318 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 391 | 0.020 |
Why?
| | Leukocytes | 1 | 2009 | 296 | 0.020 |
Why?
| | Chemotaxis | 1 | 2008 | 122 | 0.020 |
Why?
| | Child, Preschool | 1 | 2022 | 11835 | 0.020 |
Why?
| | Connective Tissue Growth Factor | 1 | 2007 | 27 | 0.020 |
Why?
| | Transplantation, Autologous | 1 | 2008 | 298 | 0.020 |
Why?
| | Young Adult | 1 | 2023 | 14176 | 0.010 |
Why?
| | Blotting, Western | 1 | 2008 | 1177 | 0.010 |
Why?
| | Cell Survival | 1 | 2008 | 1100 | 0.010 |
Why?
| | Hemodynamics | 1 | 2009 | 1115 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2008 | 1713 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1706 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2026 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2008 | 777 | 0.010 |
Why?
| | Child | 1 | 2022 | 22670 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2504 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 4142 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 2588 | 0.010 |
Why?
| | Phenotype | 1 | 2008 | 3138 | 0.010 |
Why?
| | Mice | 1 | 2009 | 18303 | 0.010 |
Why?
|
|
Ifantides's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|